HR 8981: SCALE Biology Act

HR 8981 in plain English: The SCALE Biology Act would authorize federal funding for biological research activities overseen by the Director of a federal science agency. Funding would rise from $55 million in fiscal year 2026 to $85 million in fiscal year 2030.

Stated purpose

The bill aims to create a measurement research program at the National Institute of Standards and Technology (NIST) focused on engineering biology, biomanufacturing, and biometrology — the science of measuring biological materials and processes. Its declared goal is to develop voluntary technical standards, tools, and best practices to support innovation, data accuracy, and safe development of biological technologies.

Key points

• Authorizes $55 million for fiscal year 2026 for biological research under the Director
• Increases funding each year, reaching $85 million by fiscal year 2030
• Covers fiscal years 2026 through 2030 with annual funding levels set in law

Arguments supporters make

• Having common, reliable measurement standards for biology will help American biotech companies develop and sell products more efficiently, keeping the U.S. competitive globally.
• Voluntary, consensus-based standards developed with industry input avoid heavy-handed regulation while still improving safety, data quality, and product reliability.
• Supporting graduate training and open research partnerships builds the scientific workforce and shared knowledge needed for long-term leadership in the growing bioeconomy.

Arguments opponents make

• Directing federal resources toward voluntary standards and measurement research may primarily benefit large, established biotech companies that can most easily participate in NIST consortia, while smaller players see fewer gains.
• Creating a new government program at NIST adds spending and bureaucratic infrastructure for work that private industry and existing research institutions may already be doing or could do without federal coordination.
• Voluntary standards have no enforcement mechanism, so the program may produce guidelines that companies simply ignore, limiting real-world impact on safety or data reliability.

Tradeoffs

The bill invests public funding in research infrastructure and standards that could broadly benefit U.S. biotechnology, but the benefits are indirect and long-term, while costs are immediate; choosing voluntary over mandatory standards encourages industry participation but limits the program's ability to ensure consistent safety or data practices.

Current status in Congress: In committee.

NewsClear — neutral news & congressional tracking · Bill of the Week